EPS: As of FY2025 Q2, the actual value is USD -0.29.EBIT: As of FY2025 Q2, the actual value is USD -774.81 K.<h3>Segment Revenue</h3><ul><li>The company did not report any revenues for the three months and six months ended June 30, 2025, and 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended June 30, 2025, the net loss was $775,673, compared to $1,010,919 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $1,485,228, compared to $1,982,241 for the same period in 2024.</li><li>Research and Development Costs: For the three months ended June 30, 2025, research and development costs were $60,648, a decrease from $210,708 in 2024. For the six months ended June 30, 2025, these costs were $152,105, down from $329,772 in 2024.</li><li>General and Administrative Costs: For the three months ended June 30, 2025, these costs were $714,161, compared to $798,448 in 2024. For the six months ended June 30, 2025, the costs were $1,329,644, compared to $1,646,263 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: For the six months ended June 30, 2025, net cash used in operating activities was $1,055,968, compared to $1,608,266 for the same period in 2024.</li><li>Financing Activities: The company raised $904,228 from financing activities during the six months ended June 30, 2025, primarily from a registered direct offering.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focused on the clinical development of LB-100, a protein phosphatase inhibitor, and has ongoing clinical trials in ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma.</li><li>Non-Core Business: The company is considering strategic alternatives, including mergers or acquisitions, to secure additional capital and maintain its Nasdaq listing.</li><li>Priority: The company aims to maintain compliance with Nasdaq listing requirements and has recently completed equity financings to support its operations for at least the next 12 months.</li></ul>

LIXTE BIOTECHNOLOGY HOLDINGS INC C/WTS 30/11/2025 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.29